Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $20.60.

A number of equities research analysts have recently issued reports on MSLE shares. Wells Fargo & Company set a $18.00 price objective on Satellos Bioscience in a research note on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Craig Hallum initiated coverage on shares of Satellos Bioscience in a report on Thursday, October 8th. They set a “buy” rating and a $24.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Satellos Bioscience in a research report on Monday, August 17th.

Satellos Bioscience Trading Down 1.0%

Satellos Bioscience stock opened at $6.63 on Friday. Satellos Bioscience has a 1-year low of $5.30 and a 1-year high of $13.39. The company has a fifty day simple moving average of $8.66 and a 200 day simple moving average of $8.02. The company has a market cap of $140.69 million, a P/E ratio of -3.45 and a beta of 1.51.

Satellos Bioscience (NASDAQ:MSLE) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.18). On average, equities research analysts forecast that Satellos Bioscience will post -1.86 EPS for the current year.

Institutional Investors Weigh In On Satellos Bioscience

A hedge fund recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. boosted its holdings in Satellos Bioscience Inc. (NASDAQ:MSLE) by 41.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 305,000 shares of the company’s stock after purchasing an additional 90,000 shares during the quarter. AWM Investment Company Inc. owned 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent reporting period.

Satellos Bioscience Company Profile

Satellos Bioscience Corporation (NASDAQ:MSLE) is a biotechnology company focused on developing therapies that promote the natural regeneration and repair of skeletal muscle. Its research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and rebuilding muscle tissue after injury or disease.

The company’s lead program is SAT-3247, an investigational small-molecule therapy being developed for muscle-wasting disorders, including Duchenne muscular dystrophy.